CRTX - CRTX STOCK NEWS

Cortexyme (Nasdaq: CRTX) has announced promising preclinical research for its lysine gingipain inhibitor, atuzaginstat, targeting high-risk oral potentially malignant disorders (OPMDs) linked to P. gingivalis. The research suggests that P. gingivalis may contribute to tumorigenesis and decreased survival rates. Cortexyme plans to initiate a Phase 2 trial for atuzaginstat, with an IND submission expected soon. The findings indicate a potential breakthrough in treatment options, aiming to reduce the malignancy of OPMDs and combat associated cancers.

Cortexyme, Inc. (Nasdaq: CRTX) announced positive results from the single ascending dose (SAD) portion of its Phase 1 trial for COR588, a new oral drug targeting P. gingivalis infection associated with degenerative diseases like Alzheimer’s. COR588 was well-tolerated across all tested doses (25-200 mg) with no serious adverse events reported. The pharmacokinetic profile supports once daily dosing. The company expects to present full data from the trial, including multiple ascending dose results, in Q2 2022.

Cortexyme, Inc. (Nasdaq: CRTX) announced a business update highlighting the prioritization of its next-gen lysine gingipain inhibitor, COR588, for Alzheimer’s following promising safety studies. The company also outlined its pipeline, including treatments for periodontal disease and coronavirus infections. With a preliminary cash position of $126.7 million as of year-end 2021, Cortexyme is positioned for strategic flexibility. Key 2022 milestones include advancing COR588 to Phase 2 trials and new indications for atuzaginstat (COR388) targeting oral squamous cell carcinoma.

Cortexyme (Nasdaq: CRTX) has announced the appointment of Christopher Lowe as interim CEO following the departure of Casey Lynch. David Lamond will take over as chairman of the board. Lowe, previously COO and CFO, brings over 20 years of leadership in life sciences. The board acknowledges the contributions of Lynch and Steve Dominy, the outgoing chief scientific officer. Lowe is expected to drive development of Cortexyme's pipeline, focusing on Alzheimer's treatments.

Cortexyme, Inc. (NASDAQ: CRTX) announced a full clinical hold on its atuzaginstat (COR388) Investigational New Drug application by the FDA on January 25, 2022. In response, the company is implementing a cost reduction program to extend its cash runway through 2024, focusing on the development of COR588 for Alzheimer's disease. Results from the Phase 1 SAD/MAD study are expected in Q2 2022. Cortexyme also plans to assess strategic alternatives for its coronavirus program and COR388's non-Alzheimer’s indications.

Cortexyme, Inc. (Nasdaq: CRTX) announced that CEO Casey Lynch will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 1:25 p.m. ET. The event will be virtual and accessible via a webcast on the company's Investor Calendar page. Cortexyme specializes in developing therapies targeting infectious pathogens associated with Alzheimer’s disease, particularly P. gingivalis. Their research has been confirmed by multiple labs globally and published in peer-reviewed journals.

Cortexyme (Nasdaq: CRTX) presented new data from its Phase 2/3 GAIN Trial at the CTAD 2021 conference, highlighting P. gingivalis as a potential driver of Alzheimer’s disease. The 643-participant trial explored the efficacy of atuzaginstat, showing that it slowed cognitive decline compared to placebo in patients with confirmed P. gingivalis infection. Notably, the 40 mg BID dosage demonstrated better efficacy and safety than the 80 mg BID. Despite mixed statistical significance, results point to promising therapeutic insights for Alzheimer’s treatment.

Cortexyme, Inc. (Nasdaq: CRTX) will present at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) on November 11, 2021, at 11:35 a.m. ET in Boston, Massachusetts. The presentation will feature top-line results from the GAIN Trial, showcasing the effects of Atuzaginstat in mild to moderate Alzheimer's patients. Key presenters include Michael Detke, Chief Medical Officer, and Marwan Sabbagh, lead investigator. The session will be available via the company's Investor Relations website and to registered attendees.

The Phase 2/3 GAIN Trial by Cortexyme (CRTX) evaluated atuzaginstat for Alzheimer’s in 643 patients. Overall, the study missed its co-primary endpoints of cognitive and functional improvement. However, a significant subgroup of participants with detectable P. gingivalis showed a 57% slowing of cognitive decline at the 80 mg BID dose (p=0.02). The trial validated the treatment's mechanism and supports future regulatory discussions. Most side effects were mild, with dose-related liver enzyme increases noted but no serious long-term issues reported. Additional results will be shared at CTAD 2021.